Geographic variation in invasive pneumococcal disease following pneumococcal conjugate vaccine introduction in the united states

Clinical Infectious Diseases

Volumn 53, Issue 2, 2011, Pages 137-143

  Rosen, Jennifer B ^a,j   Thomas, Ann R ^b   Lexau, Catherine A ^c   Reingold, Art ^d   Hadler, Jim L ^e   Harrison, Lee H ^f   Bennett, Nancy M ^g   Schaffner, William ^h   Farley, Monica M ⁱ   Beall, Bernard W ^a   Moore, Matt R ^a  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b OREGON PUBLIC HEALTH DIVISION   (United States)

^c MINNESOTA DEPARTMENT OF HEALTH   (United States)

^d CALIFORNIA EMERGING INFECTIONS PROGRAM   (United States)

^e YALE UNIVERSITY   (United States)

^f JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^g UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

^h VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

ⁱ EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^j NYC Department of Health and Mental Hygiene   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

PNEUMOCOCCUS VACCINE;

ADOLESCENT; ADULT; AGED; ARTICLE; CHILD; CONTROLLED STUDY; DISEASE SURVEILLANCE; FEMALE; GEOGRAPHIC DISTRIBUTION; GEOGRAPHICAL VARIATION (SPECIES); HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; NONHUMAN; PNEUMOCOCCAL INFECTION; PRESCHOOL CHILD; PRIORITY JOURNAL; PUBLIC HEALTH SERVICE; SCHOOL CHILD; SEROTYPE; STREPTOCOCCUS PNEUMONIAE; TREATMENT OUTCOME; UNITED STATES; VACCINE PRODUCTION;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CHILD; CHILD, PRESCHOOL; FEMALE; GEOGRAPHY; HUMANS; INCIDENCE; INFANT; INFANT, NEWBORN; MALE; MIDDLE AGED; PNEUMOCOCCAL INFECTIONS; PNEUMOCOCCAL VACCINES; SEROTYPING; STREPTOCOCCUS PNEUMONIAE; UNITED STATES; YOUNG ADULT;

EID: 79959695760     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cir326     Document Type: Article

References (23)

1. Centers for Disease Control and Prevention. Preventing pneumococcal disease among infants and young children: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 2000; 49:1-35.
2. Whitney CG, Pilishvili T, Farley MM, et al. Effectiveness of sevenvalent pneumococcal conjugate vaccine against invasive pneumococcal disease: a matched case-control study. Lancet 2006; 368:1495-502. (Pubitemid 44634693)
3. Whitney CG, Farley MM, Hadler J, et al. Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine. N Engl J Med 2003; 348:1737-46. (Pubitemid 36514704)
4. Centers for Disease Control and Prevention. Direct and indirect effects of routine vaccination. of children with 7-valent pneumococcal conjugate vaccine on incidence of invasive pneumococcal disease-United States, 1998-2003. MMWR 2005; 54:893-7.
5. Lexau CA, Lynfield R, Danila R, et al. Changing epidemiology of invasive pneumococcal disease among older adults in the era of pediatric pneumococcal conjugate vaccine. JAMA 2005; 294:2043-51. (Pubitemid 41539937)
6. Lacapa R, Bliss SJ, Larzelere-Hinton F, et al. Changing epidemiology of invasive pneumococcal disease among White Mountain Apache persons in the era of the pneumococcal conjugate vaccine. Clin Infect Dis 2008; 47:476-84.
7. Singleton RJ, Hennessy TW, Bulkow LR, et al. Invasive pneumococcal disease caused by nonvaccine serotypes among Alaska native children with high levels of 7-valent pneumococcal conjugate vaccine coverage. JAMA 2007; 297:1784-92. (Pubitemid 46658647)
8. Messina AF, Katz-Gaynor K, Barton T, et al. Impact of the pneumococcal conjugate vaccine on serotype distribution and antimicrobial resistance of invasive Streptococcus pneumoniae isolates in Dallas, TX, children from 1999 through 2005. Pediatr Infect Dis J 2007; 26:461-7. (Pubitemid 46847303)
9. Hsu K, Pelton S, Karumuri S, Heisey-Grove D, Klein J. Populationbased surveillance for childhood invasive pneumococcal disease in the era of conjugate vaccine. Pediatr Infect Dis J 2005; 24:17-23. (Pubitemid 40353311)
10. Byington CL, Samore MH, Stoddard GJ, et al. Temporal trends of invasive disease due to Streptococcus pneumoniae among children in the intermountain west: emergence of nonvaccine serogroups. Clin Infect Dis 2005; 41:21-9. (Pubitemid 40863739)
11. Black S, Shinefield H, Baxter R, et al. Postlicensure surveillance for pneumococcal invasive disease after use of heptavalent pneumococcal conjugate vaccine in Northern California Kaiser Permanente. Pediatr Infect Dis J 2004; 23:485-9. (Pubitemid 38802290)
12. Pelton SI, Huot H, Finkelstein JA, et al. Emergence of 19A as virulent and multidrug resistant pneumococcus in Massachusetts following universal immunization of infants with pneumococcal conjugate vaccine. Pediatr Infect Dis J 2007; 26:468-72. (Pubitemid 46847304)
13. Centers for Disease Control and Prevention. Invasive pneumococcal disease in children 5 years after conjugate vaccine introduction-eight states, 1998-2005. MMWR 2008; 57:144-8.
14. National Center for Immunization and Respiratory Diseases, CDC. National immunization survey, 2009.
15. Flannery B, Schrag S, Bennett NM, et al. Impact of childhood vaccination on racial disparities in invasive Streptococcus pneumoniae infections. JAMA 2004; 291:2197-203. (Pubitemid 38608168)
16. Fry AM, Facklam RR, Whitney CG, Plikaytis BD, Schuchat A. Multistate evaluation of invasive pneumococcal diseases in adults with human immunodeficiency virus infection: serotype and antimicrobial resistance patterns in the United States. J Infect Dis 2003; 188:643-52. (Pubitemid 37115176)
17. Harrison L, Dwyer D, Billmann L, Kolczak M, Schuchat A. Invasive pneumococcal infection in Baltimore, MD: implications for immunization policy. Arch Intern Med 2000; 160:89-94. (Pubitemid 30040977)
18. Davies TA, Yee YC, Bush K, Sahm D, Evangelista A, Goldschmidt R. Effects of the 7-valent pneumococcal conjugate vaccine on U.S. levofloxacin-resistant Streptococcus pneumoniae. Microb Drug Resist 2008; 14:187-96.
19. Kyaw MH, Lynfield R, Schaffner W, et al. Effect of introduction of the pneumococcal conjugate vaccine on drug-resistant Streptococcus pneumoniae. N Engl J Med 2006; 354:1455-63.
20. Moore MR, Gertz RE, Woodbury RL, et al. Population snapshot of emergent Streptococcus pneumoniae serotype 19A in the United States, 2005. J Infect Dis 2008; 197:1016-27. (Pubitemid 351590031)
21. Greenberg D, Givon-Lavi N, Sharf AZ, Vardy D, Dagan R. The association between antibiotic use in the community and nasopharyngeal carriage of antibiotic-resistant Streptococcus pneumoniae in Bedouin children. Pediatr Infect Dis J 2008; 27:776-82.
22. Dagan R. Increased importance of antibiotic-resistant (AR) S. pneumoniae serotype 19A (Pn19A) in acute otitis media (AOM) occurring before introduction of 7-valent pneumococcal conjugate vaccine (PCV7) in Southern Israel. 47th Interscience Conference on Antimicrobials and Chemotherapy. Chicago, IL: American Society for Microbiology, 2007.
23. Hicks LA, Suda KJ, Roberts RM, et al. Antimicrobial prescription data reveal wide geographic variability in antimicrobial use in the United States, 2009. 48th Annual Meeting of the Infectious Diseases Society of America. Vancouver, Canada: Infectious Disease Society of America, 2010.